MAPT and Alzheimer disease: They operate at different stages of the clinical progression of AD, through multiple neurotoxic mechanisms, such as receptor binding and disturbances of receptor-activated signal transduction pathway, mitochondrial dysfunction, dysregulation of Ca2+ homeostasis, alterations of tau metabolism [73].